University of Calgary

Ahmed Atef Ahmed Ali

  • Postdoctoral Associate

Biography

Ahmed Atef Ahmed Ali has a broad and interdisciplinary academic background that includes a Bachelor (Honors) of Pharmaceutical Sciences, a Master of Microbiology and Immunology, and a PhD in Life Sciences - Molecular and Cellular Biology degrees from Top World-class academic institutions. He is currently working at the University of Calgary, Alberta, Canada. Since 2017, Ahmed worked as a Tenured Assistant Professor researcher and Principal Investigator at College of Medicine, Taipei Medical University. He is leading his research group which is specialized in Drug Formulation & Delivery Systems, Neuroscience, Cancer Research, Therapeutic Mesenchymal Stem Cells, induced Pluripotent Stem Cells, Microfluidics, Pharmaceutics, and Translational Imaging Research. Furthermore, he is a registered Clinical Specialist of Microbiology and Immunology and registered Pharmacist at the Ministry of Health and Population.

Ahmed Atef Ahmed Ali obtained his PhD degree from Academia Sinica (World's 18th rank of the Reuter's World's Most Innovative Institutions list of 2019) and National Defense Medical Center, Taiwan. He received the honorary “First Excellence Academic Performance” award for the cumulative academic achievements among Academia Sinica and National Defense Medical Center PhD graduates in 2017, and was selected as the Outstanding Graduate Student of the 2016 graduates of the Taiwan International Graduate Program of Academia Sinica. He received several awards and prizes for his contribution in advancing the research. Owing to his excellent communication, presentation, & negotiation skills, he was able to initiate and maintain several collaboration projects both locally and internationally. He has been working in the academic teaching & research fields since 2003.

Publications

 

1.     Mendiratta S, AAtef AA, Hejazi SH, Gates I. Dual Stimuli-responsive Pickering Emulsions from Novel Magnetic Hydroxyapatite Nanoparticles and Their Characterization Using Microfluidic Platform. Langmuir. 2021.

2.     AAtef AA, Lee YR, A Wu, V Yadav, D Yu, Huang HS. Structure-based strategies for synthesis, lead optimization and biological evaluation of N-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivatives as potential multi-target anticancer agents. Arab J Chem, 2021.

3.     AAtef AA *, Rami Ahmad Shahror, Kai-Yun Chen. Efficient labeling of mesenchymal stem cells for high sensitivity long-term MRI monitoring in live mice brains. Int. J. Nanomed. 2020.

4.     Mendiratta S, Hussein M, Nasser HA, AAtef AA *. Multidisciplinary role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing Blood Brain Barrier to Treatment. Part Part Syst Charact. 2019.

5.     Shahror RA, AAtef AA, Wu CC, Chiang YH, Chen KY. Enhanced Homing of Mesenchymal Stem Cells Overexpressing Fibroblast Growth Factor 21 to Injury Site in a Mouse Model of Traumatic Brain Injury. Int J Mol Sci, 2019.

6.     Mendiratta S, AAtef AA *. Recent Advances in Functionalized Mesoporous Silica Frameworks for Efficient Desulfurization of Fuels. Nanomaterials. 2020.

7.     Hsu FT, Liu HS, AAtef AA, Chou SY, Hsu TI, Liu YC, Chiang IT. Regorafenib Reverses Temozolomide-induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. Cell Reports. 2021 (under review).

8.     Hsu FT, Liu HS, AAtef AA, Tsai PH, Kao YC, Lu CF, Huang HS, Chen CY. Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system. Nanomedicine, 2018.

9.     Fann LY, Chen Y, Chu DC, Weng SJ, Chu HC, Wu AT, AAtef AA, Chen TC, Huang HS, Ma KH. Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways. Oncotarget, 2017.

10.  Chen HL, Hsu FT, Kao YJ, Liu HS, Huang WZ, Lu CF, Tsai PH, AAtef AA, Lee GA, Chen RJ, Chen CY. Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro. J Nanobiotechnology, 2017.

11.  AAtef AA, Hsu FT, Hsieh CL, Shiau CY, Chiang CH, Wei ZH, Chen CY, Huang HS. Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI. Scientific Reports, 2016.

12.  AAtef AA, Lee YR, Chen TC, Chen CL, Lee CC, Shiau CY, Chiang CH, Huang HS. Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination. PLOS ONE, 2016.

13.  Chen CL; Lee CC, Liu FL, Chen TC, AAtef AA, Chang DM, Huang HS. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem, 2016.

14.  Lee CC, Liu FL, Chen CL, Chen TC, AAtef AA, Chang DM, Huang HS. Novel inhibitors of RANKL-induced osteoclastogenesis: Deign, synthesis, and biological evaluation of 6-(2,4-difluorophenyl)-3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones. Bioorg Med Chem, 2015.

15.  Chen CL, Chen TC, Lee CC, Shih LC, Lin CY, Hsieh YY, AAtef AA, Huang HS. Synthesis and evaluation of new 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer agents. Arab J Chem, 2015.

16.  Lee YR; Chen, TC, Lee CC, Chen CL, AAtef AA, Tikh A, Guh JH, Huang HS. Ring fusion strategy for synthesis and lead optimization of sulfur-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising scaffold of antitumor agents. Eur J Med Chem, 2015.

17.  Chen CL, Liu FL, Lee CC, Chen TC, AAtef AA, Sytwu HK, Chang DM, Huang HS. Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption. J Med Chem, 2014.

18.  Chen CL, Liu FL, Lee CC, Chen TC, Chang WW, Guh JH, AAtef AA, Huang HS. Ring Fusion Strategy for the Synthesis of Anthra[2,3-d]oxazole-2-thione-5,10-dione Homologues as DNA Topoisomerase Inhibitors and as Antitumor Agents. Eur J Med Chem. 2014.

19.  A study of the microbial quality, preservation and safety of some ophthalmic pharmaceutical and cosmetic preparations” A thesis submitted to Faculty of Pharmacy in partial fulfillment of the requirements for the Degree of Master of Microbiology and Immunology.

20.  Formulation of smart cancer-targeted theranostic nanoparticles, molecular targets identification and biological evaluation of small-molecule drugs” A thesis submitted to Molecular and Cell Biology Program, Taiwan International Graduate Program of National Defense Medical Center and Academia Sinica in partial fulfillment of the requirements for the Degree of philosophy in Molecular and Cell Biology.

 

Patents

 

  1. Dextran magnetic iron nanoparticle, preparation method and use thereof for cancer comprising a dextran layer, a magnetic iron nanoparticle and an active drug, and useful for the treatment of cancer and for imaging. Inventors: HUANG HSU-SHAN; CHEN CHENG-YU; AATEF AA; HSU FEI-TING. Bibliographic data: TW201821061 (A) ― 2018-06-16
  2. 葡聚糖磁性铁奈米颗粒、制备及在治疗癌症与造影的用途. Inventors:CHEN CHENG-YU; AATEF AA; HSU FEI-TING; HUANG HSU-SHAN.  Bibliographic data: WO2018098705A1

Photograph of Ahmed Atef Ahmed Ali
Powered by UNITIS. More features.